AI Develops a New Vaccine Type to Combat Viruses and Pandemics
Researchers have utilized artificial intelligence (AI) to create a "fundamentally new" vaccine designed to protect against a broad range of viruses and potentially prevent future pandemics. The team at the University of Cambridge reports this is the first instance where a vaccine's crucial component has been entirely designed by AI and subsequently tested in humans.
The vaccine targets all coronaviruses, encompassing all Covid variants as well as viruses currently infecting animals that could potentially trigger the next pandemic. Although the research remains in its early phases, the team is concurrently developing vaccines aimed at influenza and Ebola.
Vaccines function by training the immune system to recognize infections, thereby enhancing the body's ability to combat them. However, many viruses frequently mutate, altering their appearance and rendering vaccines obsolete. This is why Covid and seasonal flu vaccines require regular updates.
"We're always behind," said Prof Jonathan Heeney from the University of Cambridge.
"What we're trying to do is get ahead of the curve" and be so far ahead that vaccines could protect against new outbreaks or pandemics.
Vaccines and Viral Mutation Challenges
Vaccines were instrumental during the Covid-19 pandemic but had to be designed from scratch and continuously updated as the virus evolved.
How Does the AI-Designed Vaccine Work?
Traditional vaccine development typically uses a current viral strain as a basis. In contrast, Cambridge researchers gathered genetic codes — the biological instruction manuals — from various coronaviruses identified through surveillance programs monitoring potential viral threats.
An AI system analyzed these genetic sequences and designed a "super-antigen" capable of training the immune system to provide protection against the entire coronavirus family. This includes protection against mutated viruses or new infections transmitted from animals to humans.
Antigens are the essential components of vaccines, as they are what the immune system learns to target.
Heeney stated this is the first time an AI-designed antigen has been trialled in humans. He described the technology as "surprising all of us" and "amazing what we can do with it for the good of humanity."
Heeney told : "This is about making vaccines that protect us, not just from today's viruses, but protect us from what can cause the next outbreak or disease.
This is a fundamental shift in how we prepare for pandemics."
Clinical Trials and Immune Response
The initial trials involved 39 participants and aimed to evaluate the vaccine's safety. A subsequent study with approximately 200 participants will provide more comprehensive data on how effectively the vaccine trains the immune system.
The results, published in the Journal of Infection, indicated that the immune response was "modest," yet the findings have generated considerable excitement within the scientific community.
Prof Saul Faust, who conducted some trials at the University of Southampton, commented that the AI design "definitely has potential" and is "really exciting."
He told the BBC: "What's really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing."
Ongoing Research on Other Vaccines
The Cambridge team is also conducting animal studies on universal seasonal flu vaccines that would not require annual adaptation, as well as an H5N1 bird flu vaccine. This is significant given the current devastation of bird populations by H5N1 and the risk of it becoming a human pandemic.
Additionally, research is underway on vaccines for viral haemorrhagic fevers, including Ebola species. The ongoing outbreak in the Democratic Republic of Congo involves a species for which no vaccine currently exists.
Expert Opinions on AI in Vaccine Development
Prof Andy Pollard, director of the Oxford Vaccine Group and not involved in the study, noted that this approach is producing compelling evidence in animal research.
"It's fascinating data and people wouldn't have predicted they'd be able to generate these immune responses," he told .
He emphasized that the true test will be the results of human trials, as human immune systems differ from laboratory mice, having been shaped by years of exposure to infections.
More broadly, Prof Pollard stated that AI will be a "game changer" for vaccine research. AI tools have the potential to predict immune system responses to vaccines, accelerating development and ultimately saving lives.
Prof Marian Knight, scientific director for the National Institute for Health and Care Research, said: "The remarkable success of this AI-designed 'super-antigen' trial marks a pivotal leap forward in our ability to deliver broad, lasting viral protection."
Science Minister Lord Vallance said: "Another British science success story, this is a great example of how we can bring our research expertise together with AI to deliver new treatments.
With the first human trials showing positive results, this work could help speed up the roll out vaccines to benefit people all over the world for the long-term."
